Molecular aspects of allergy

Area of Science:

• Immunology
• Allergy Research
• Pharmacology

Background:

• Atopic diseases including asthma, rhinitis, eczema, and food allergies have significantly increased worldwide over the past two decades.
• Hypotheses for this rise include increased allergen exposure or reduced immune system stimulation during development.
• Allergic diseases involve a Th2 immune response, increased type 2 cytokines, and elevated immunoglobulin E (IgE), leading to inflammation.

Purpose of the Study:

• To investigate the role of the IgE-Fc epsilon RI interaction in the pathogenesis of atopic diseases.
• To explore novel therapeutic strategies targeting this interaction for prevention and treatment.
• To evaluate the efficacy of non-anaphylactogenic antibodies in blocking IgE-Fc epsilon RI signaling.

Main Methods:

• Review of current hypotheses regarding the increase in atopic diseases.
• Analysis of the effector phase of atopy involving Fc epsilon RI on various cells.
• Examination of therapeutic strategies focusing on inhibiting the IgE-Fc epsilon RI pathway.

Main Results:

• The effector phase of atopy is initiated by IgE binding to Fc epsilon RI, triggering histamine release.
• Autoantibodies against Fc epsilon RI alpha-chain may contribute to diseases like chronic idiopathic urticaria (CIU).
• Clinical trials with a humanized anti-IgE antibody demonstrated reduced symptoms and medication use in asthma and allergic rhinitis.

Conclusions:

• Interruption of the atopic cascade at the IgE-Fc epsilon RI interaction level is an effective therapeutic approach.
• Non-anaphylactogenic antibodies targeting IgE-Fc epsilon RI represent an attractive therapy for atopic diseases.
• This strategy offers a promising avenue for preventive and potentially curative treatments for allergies.